Effects of n-butyrate on Epstein-Barr virus-carrying lymphoma lines.
n-Butyrate has been shown to induce Epstein-Barr virus (EBV) antigen synthesis in certain EBV-carrying lymphoma lines (Luka et al., 1979). We have studied the effect of n-butyrate on two EBV-positive Burkitt lymphoma lines by immuno-fluorescence and electron microscopy. In the producer line P3HR-1, the drug induced not only early antigen (EA) and virus capsid antigen (VCA) synthesis, as shown before, but also increased the number of cells containing virus particles. The transition from VCA expression to the formation of virus particles was much more effective in treated cells than in EBV antigen-producing cells of the same line. The productive cycle was associated with the development of characteristic morphological changes. In the non-producer Raji cells, n-butyrate induced EA in only a minor fraction of the cells. There were, however, clear signs of differentiation in the direction of plasma cells. Two days after the addition of n-butyrate 80% of the Raji cells could be classified as plasmablasts. After 72 h, 20% of the cells appeared as typical plasma cells.
D000956:Antigens, Viral / Q000096:biosynthesis; D002051:Burkitt Lymphoma; D002087:Butyrates / Q000494:pharmacology*; D020148:Butyric Acid; D002460:Cell Line; D003588:Cytopathogenic Effect, Viral; D004854:Herpesvirus 4, Human / Q000187:drug effects* / Q000254:growth & development / Q000276:immunology; D006801:Humans; D014775:Virus Activation / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
D000956:Antigens, Viral; D002087:Butyrates; D020148:Butyric Acid